Revlimid vs Darzalex
Side-by-side drug price comparison from Medicare Part D data
Verdict
Darzalex costs 11% less per claim than Revlimid ($11346.00 vs $12786.00). Darzalex has a generic alternative available. Total Medicare spending: Revlimid at $7.8B vs Darzalex at $3.2B.
| Metric | Revlimid | Darzalex |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $12,786 | $11,346* |
| Total Medicare Spending Total Medicare Part D spending on this drug | $7.8B | $3.2B |
| Total Claims | 612,000 | 286,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | -3.4%* | 21.4% |
| Generic Available | No | Yes |
| Condition | Cancer | Cancer |
| Total Beneficiaries | 58,000 | 32,000 |
Darzalex costs 11% less per claim than Revlimid ($11346.00 vs $12786.00). Darzalex has a generic alternative available. Total Medicare spending: Revlimid at $7.8B vs Darzalex at $3.2B.
Explore More
Comparing Revlimid and Darzalex on U.S. Medicare prescription-drug pricing requires lining up the underlying CMS Medicare Part D Drug Spending data data side by side. The table above runs the comparison on the canonical fields; the narrative below identifies the factor or factors that drive the most meaningful difference between the two.
Practical use of the comparison: read the data above, then drill into the individual Revlimid and Darzalex detail pages for the underlying breakdown. A pairwise comparison answers the relative question; the per-entity pages answer the absolute question.
Source: CMS Medicare Part D Spending, 2026.